Node-negative predictive clinical trial results
Only the Oncotype DX Breast Recurrence Score test predicts the likelihood of chemotherapy benefit for pre- and post-menopausal, node-negative patients.2
25%
of patients with a low Recurrence Score® result (0-25) had high clinical risk* and may have been overtreated without the Recurrence Score result†
*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
†Assuming that adjuvant chemotherapy would have been recommended because of the high clinical risk.
43%
of patients with a high Recurrence Score result (26-100) had low clinical risk‡ and may have been undertreated without the Recurrence Score result§
†Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.
§Assuming that adjuvant chemotherapy would not have been recommended because of the low clinical risk.
NSABP B-20 study: low Recurrence Score result predicted little to no benefit from chemotherapy
The NSABP B-20 study was performed on a cohort of 651 patients with ER+, node-negative breast cancer from the NSABP B-20 trial. The objective of this study was to determine whether the Recurrence Score result predicted the likelihood of chemotherapy benefit.2
NSABP B-20 study: high recurrence Score result predicted large benefit from chemotherapy
Prospective analysis of archived tissue from 651 patients with ER-positive, node-negative, invasive breast cancer treated with tamoxifen or tamoxifen plus CMF/MF. Approximately 45% of the patients were <50 years of age, 2/3 of tumors were ≤2.0 cm in size, and 16% of tumors were progesterone receptor-negative.2
-
References
Use our online physician portal
Order tests, access results, receive updates, and more in one place.
Sign up now